Potential applications of magnetic particles to detect and treat Alzheimer's disease

Nanoscale Research Letters

Volumn 9, Issue 1, 2014, Pages 1-10

  Busquets, Maria Antònia ^a,b   Sabaté, Raimon ^a,b   Estelrich, Joan ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Amyloid; Bio barcode assay; Gadolinium; Magnetic resonance imaging; Superparamagnetic iron oxide nanoparticles

Indexed keywords

BAR CODES; DIAGNOSIS; GADOLINIUM; GLYCOPROTEINS; IRON OXIDES; MAGNETIC RESONANCE IMAGING; METAL NANOPARTICLES; NEURODEGENERATIVE DISEASES; PEPTIDES; SUPERPARAMAGNETISM;

AMYLOID; BIO-BARCODE AMPLIFICATION ASSAY; BIO-BARCODE ASSAYS; CORE/SHELL NANOPARTICLES; DETECTION AND DIAGNOSIS; MAGNETIC NANO-PARTICLES; NEURODEGENERATIVE DISORDERS; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLES;

NANOMAGNETICS;

EID: 84919917935     PISSN: 19317573     EISSN: 1556276X     Source Type: Journal    
DOI: 10.1186/1556-276X-9-538     Document Type: Article

References (55)

1. Harper JD, Lansbury PT Jr: Models of amyloid seeding in Alzheimer’s disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins.Annu Rev Biochem 1997, 66:385–407. 10.1146/annurev.biochem.66.1.385
2. Gorman PM, Chakrabartty A: Alzheimer β-amyloid peptides: structures of amyloid fibrils and alternate aggregation products.Biopolymers 2001, 60:381–394. 10.1002/1097-0282(2001)60:5<381::AID-BIP10173>3.0.CO;2-U
3. Murphy RM: Peptide aggregation in neurodegenerative disease.Annu Rev Biomed Eng 2002, 4:155–174. 10.1146/annurev.bioeng.4.092801.094202
4. Soto C: Unfolding the role of protein misfolding in neurodegenerative diseases.Nature Rev Neurosci 2003, 4:49–60. 10.1038/nrn1007
5. Glenner GG, Wong CW: Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein.Biochem Biophys Res Commun 1984, 120:885–890. 10.1016/S0006-291X(84)80190-4
6. Yankner BA: New clues to Alzheimer's disease: unraveling the roles of amyloid and tau.Nat Med 1996, 2:850–852. 10.1038/nm0896-850
7. Hardy J, Selkoe DJ: The amyloid hypothesis of Alzheimer’s disease: progress and problems of the road to therapeutics.Science 2002, 297:353–356. 10.1126/science.1072994
8. Hartley DM, Walsh DM, Ye CP, Diehl T, Vasques S, Vassilev PM, Teplow DB, Selkoe DJ: Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons.J Neurosci 1999, 19:8876–8884.
9. Klein WL, Krafft GA, Finch CE: Targeting small Aβ oligomers: the solution to an Alzheimer’s disease conundrum?Trends Neurosci 2001, 24:219–224. 10.1016/S0166-2236(00)01749-5
10. Westerman MA, Cooper-Blacketer D, Mariash A, Kotilinek L, Kawarabayashi T, Younkin LH, Carlson GA, Younkin SG, Ashe KH: The relationship between Aβ and memory in the Tg2576 mouse model of Alzheimer's disease.J Neurosci 2002, 22:1858–1867.
11. Kawarabayashi T, Shoji M, Younkin LH, Lin WL, Dickson DW, Murakami T, Matsubara E, Abe K, Ashe KH, Younkin SG: Dimeric amyloid β protein rapidly accumulates in lipid rafts followed by apolipoprotein E and phosphorylated τ accumulation in the Tg2576 mouse model of Alzheimer’s disease.J. Neurosci 2004, 24:3801–3809. 10.1523/JNEUROSCI.5543-03.2004
12. Chatterjee K, Sarkar S, Jagajjanani Rao K, Santanu Paria S: Core/shell nanoparticles in biomedical applications.Adv Colloid Interface Sci 2014, 209:8–39.
13. Zhang I, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC: Nanoparticles in medicine: therapeutic applications and developments.Clin Pharm Ther 2008, 83:761–769. 10.1038/sj.clpt.6100400
14. Sounderya N, Zhang Y: Use of core/shell structured nanoparticles for biomedical applications.Recent Pat Biomed Eng 2008, 1:34–42. 10.2174/1874764710801010034
15. Tartaj P: Nanomagnets for biomedical applications. In Encyclopedia of Nanoscience and Nanotechnology, Volume 6. Edited by: Nalwa HS. Valencia: American Scientific Publishers; 2003:823–842.
16. Akbarzadeh A, Samiei M, Davaran S: Magnetic nanoparticles: preparation, physical properties, and applications in biomedicine.Nanoscale Res Lett 2012, 7:144. 10.1186/1556-276X-7-144
17. Silva GA: Nanotechnology approaches to crossing the blood–brain barrier and drug delivery to the CNS.BMC Neurosci 2008,9(Suppl. 3):S4.
18. Xu L, Zhang H, Wu Y: Dendrimer advances for the central nervous system delivery of therapeutics.ACS Chem Neurosci 2013, 5:2–13.
19. Goldsmith M, Abramovitz L, Peer D: Precision nanomedicine in neurodegenerative diseases.ACS Nano 2014, 8:1958–1965. 10.1021/nn501292z
20. Amiri H, Saeidi K, Borhani P, Manafirad A, Ghavami M, Zerbi V: Alzheimer’s disease: pathophysiology and applications of magnetic nanoparticles as MRI theranostic agents.ACS Chem Neurosci 2013, 4:1417–1429. 10.1021/cn4001582
21. Lam T, Pouliot P, Avti PK, Lesage F, Kakkar AK: Superparamagnetic iron oxide based nanoprobes for imaging and theranostics.Adv Colloid Interface Sci 2013, 199–200:95–113.
22. Yoo D, Lee J-H, Shin T-H, Cheon J: Theranostic magnetic nanoparticles.Acc Chem Rev 2011, 10:863–874.
23. Kirschvink JL, Kobayashi-Kirschvink A, Woodford BJ: Magnetic biomineralization in the human brain.Proc Natl Acad Sci USA 1992, 89:7683–7687. 10.1073/pnas.89.16.7683
24. Dobson J: Investigation of age-related variations in biogenic magnetite levels in the human hippocampus.Exper Brain Res 2002, 144:122–126. 10.1007/s00221-002-1066-0
25. Haunot D, Pankhurst QA, Kahn N, Dobson J: Preliminary evaluation of nanoscale biogenic magnetite in Alzheimer’s disease.Proc Roy Soc B Biol Letters 2003, 270:S62-S64. 10.1098/rsbl.2003.0012
26. Pankhurst QA, Hautot D, Kahn N, Dobson J: Increase levels of magnetic iron compounds in Alzheimer’s disease.J Alzheimer’s Dis 2008, 13:49–52.
27. Dobson J, Bowtell R, García-Prieto A, Pankhurst Q: Safety implications of high-field MRI: actuation of endogenous magnetic iron oxides in the human body.PLos One 2009, 4:e5431. 10.1371/journal.pone.0005431
28. Wadghiri YZ, Sigurdsson EM, Sadowski M, Elliott JI, Li Y, Scholtzova H, Tang CY, Aguinaldo G, Pappolla M, Duff K, Wisniewski T, Turnbull DH: Detection of Alzheimer’s amyloid in transgenic mice using magnetic resonance microimaging.Magn Reson Med 2003, 50:293–302. 10.1002/mrm.10529
29. Sillerud LO, Solberg NO, Chamberlain R, Orlando RA, Heidrich JE, Brown DC, Brady CI, Vander Jagt TA, Garwood M, Vander Jagt DL: SPION-enhanced magnetic resonance imaging of Alzheimer’s disease plaques in AbetaPP/PS-1 transgenic mouse brain.J Alzheimer’s Dis 2013, 34:349–365.
30. Yang J, Wadghiri YZ, Hoang DM, Tsui W, Sun Y, Chung E, Li Y, Wang A, de Leon M, Wisniewski T: Detection of amyloid plaques targeted by USPIO-Aβ1–42 in Alzheimer’s disease transgenic mice using magnetic resonance microimaging.NeuroImage 2011, 55:1600–1609. 10.1016/j.neuroimage.2011.01.023
31. Di Domizio J, Zhang R, Stagg LJ, Gagea M, Zhuo M, Ladbury JE, Cao W: Binding with nucleic acids or glycosaminoglycans converts soluble protein oligomers to amyloid.J Biol Chem 2012, 287:736–747. 10.1074/jbc.M111.238477
32. Kouyoumdjian H, Zhu DC, El-Dakdouki MH, Lorenz K, Chen J, Li W, Huang X: Glyconanoparticle aided detection of β-amyloid by magnetic resonance imaging and attenuation of β-amyloid induced cytotoxicity.ACS Chem Neurosci 2013, 4:575–584. 10.1021/cn3002015
33. Poduslo JF, Wengenack TM, Curran GL, Wisniewski T, Sigurdsson EM, Macura SI, Borowski BJ, Jack CR Jr: Molecular targeting of Alzheimer’s amyloid plaques for contrast-enhanced magnetic resonance imaging.Neurobiol Dis 2002, 11:315–329. 10.1006/nbdi.2002.0550
34. Petiet A, Santin M, Bertrand A, Wiggins CJ, Petit F, Houitte D, Hantraye P, Benavides J, Debeir T, Rooney T, Dhenain M: Gadolinium-staining reveals amyloid plaques in the brain of Alzheimer’s transgenic mice.Neurobiol Aging 2012, 33:1533–1544. 10.1016/j.neurobiolaging.2011.03.009
35. Martins AF, Morfin JF, Kubíčková A, Kubíček V, Buron F, Suzenet F, Salerno M, Lazar AN, Duyckaerts C, Arlicot N, Guilloteau D, Geraldes CFGG, Tóth E: PiB-conjugated, metal-based imaging probes: multimodal approaches for the visualization of β-amyloid plaques.ACS Med Chem Lett 2013, 4:436–440. 10.1021/ml400042w
36. Beckmann N, Gérard C, Abramowski D, Cannet C, Staunfenbiel M: Noninvasive magnetic resonance imaging detection of cerebral amyloid angiopathy-related microvascular alterations using superparamagnetic iron oxide particles in APP transgenic mouse models of Alzheimer’s disease: application to passive Aβ immunotherapy.J Neurosci 2011, 31:1023–1031. 10.1523/JNEUROSCI.4936-10.2011
37. Skaat H, Margel S: Synthesis of fluorescent-maghemite nanoparticles as multimodal imaging agents for amyloid-β fibrils detection and removal by a magnetic field.Biochem Biophys Res Commun 2009, 386:645–649. 10.1016/j.bbrc.2009.06.110
38. Choi JS, Choi HJ, Jung DC, Lee JH, Cheon J: Nanoparticle assisted magnetic resonance imaging of the early reversible stages of amyloid β self-assembly.Chem Commun 2008, 19:2197–2199.
39. Georganopoulou DG, Chang L, Nam J-M, Thaxton CS, Mufson EJ, Klein WL, Mirkin CA: Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer’s disease.Proc Natl Acad Sci USA 2005, 102:2273–2276. 10.1073/pnas.0409336102
40. Nam JM, Thaxton CS, Mirkin CA: Nanoparticle-based bio-bar codes for the ultrasensitive detection of proteins.Science 2003, 301:1884–1886. 10.1126/science.1088755
41. Keating CD: Nanoscience enables ultrasensitive detection of Alzheimer’s biomarker.Proc Natl Acad Sci USA 2005, 102:2263–2264. 10.1073/pnas.0500024102
42. Chiu MJ, Yang SY, Horng HE, Yang CC, Chen TF, Chieh JJ, Chen HH, Chen TC, Ho CS, Chang SF, Liu HC, Hong CY, Yang HC: Combined plasma biomarkers for diagnosing mild cognition impairment and Alzheimer’s disease.ACS Chem Neurosci 2013, 4:1530–1536. 10.1021/cn400129p
43. csuperconducting quantum interference devices.J App Phys 2008, 103:014703–1-6.
44. Yang CC, Yang SY, Chieh JJ, Horng HE, Hong CY, Chen KH, Shih BY, Chen TF, Chiu MJ: Biofunctionalized magnetic nanoparticles for specifically detecting biomarkers of Alzheimer’s disease in vitro.ACS Chem Neurosci 2011, 2:500–505. 10.1021/cn200028j
45. Ranc V, Markova Z, Hajduch M, Prucek R, Kvitek L, Kaslik J, Safarova V, Zboril R: Magnetically assisted surface-enhanced Raman scattering selective determination of dopamine in an artificial cerebrospinal fluid and a mouse striatum using Fe3O4/Ag nanocomposite.Anal Chem 2014, 86:2939–2946. 10.1021/ac500394g
46. Chopra K, Misra S, Kuhad A: Current perspectives on pharmacotherapy of Alzheimer’s disease.Expert Opin Pharmacother 2011, 12:335–350. 10.1517/14656566.2011.520702
47. Corbett A, Ballard C: New and emerging treatments for Alzheimer’s disease.Expert Opin Emerging Drugs 2012, 17:147–156. 10.1517/14728214.2012.675327
48. Estelrich J, Linazasoro G: Potential applications of nanotechnologies to neurodegenerative diseases (Parkinson’s disease and Alzheimer’s disease). In Controlled Release Systems: Advances in Nanobottles and Active Nanoparticles. Edited by: Pastorin G, Forcada J, Van der Werk A. Singapore: Pan Stanford Publishing; in press
49. Brambilla D, Le Droumaguet B, Nicolas J, Hashemi SH, Wu LP, Moghimi SM, Couvreur P, Andrieux K: Nanotechnologies for Alzheimer's disease: diagnosis, therapy, and safety issues.Nanomed: Nanotech Biol Med 2011, 7:521–540. 10.1016/j.nano.2011.03.008
50. Sabaté R, Estelrich J: Stimulatory and inhibitory effects of alkyl bromide surfactants on β-amyloid fibrillogenesis.Langmuir 2005, 21:6944–6949. 10.1021/la050472x
51. Bokvist M, Lindstrom F, Watts A, Grobner G: Two types of Alzheimer’s β-amyloid(1–40) peptide membrane interactions: aggregation preventing transmembrane anchoring versus accelerated surface fibril formation.J Mol Biol 2004, 335:1039–1049. 10.1016/j.jmb.2003.11.046
52. Cabaleiro-Lago C, Quinlan-Pluck F, Lynch I, Dawson KA, Linse S: Dual effect of amino modified polystyrene nanoparticles on amyloid protein fibrillation.ACS Chem Neurosci 2010, 1:279–287. 10.1021/cn900027u
53. Perthinez TA, Bouchard M, Smith RAG, Dobson CM, Smith LJ: Secondary structure and interfacial aggregation of amyloid-β(1–40) on sodium dodecyl sulfate micelles.FEBS Lett 2002, 529:193–197. 10.1016/S0014-5793(02)03333-1
54. Linse S, Cabaleiro-Lago C, Xue WF, Lynch I, Lindman S, Thulin E, Radford SE, Dawson KA: Nucleation of protein fibrillation by nanoparticles.Proc Natl Acad Sci USA 2007, 104:8691–8696. 10.1073/pnas.0701250104
55. Mahmoudi M, Quinlan-Pluck F, Monopoli MP, Sheinani S, Vali H, Dawson KA, Lynch I: Influence of the physicochemical properties of superparamagnetic iron oxide nanoparticles on amyloid β protein fibrillation in solution.ACS Chem Neurosci 2013, 4:475–485. 10.1021/cn300196n